title: Analysis of the small RNA transcriptional response in multidrug-resistant Staphylococcus aureus after antimicrobial exposure.
abstract: The critical role of noncoding small RNAs (sRNAs) in the bacterial response to changing conditions is increasingly recognized. However, a specific role for sRNAs during antibiotic exposure has not been investigated in Staphylococcus aureus. Here, we used Illumina RNA-Seq to examine the sRNA response of multiresistant sequence type 239 (ST239) S. aureus after exposure to four antibiotics (vancomycin, linezolid, ceftobiprole, and tigecycline) representing the major classes of antimicrobials used to treat methicillin-resistant S. aureus (MRSA) infections. We identified 409 potential sRNAs and then compared global sRNA and mRNA expression profiles at 2 and 6 h, without antibiotic exposure and after exposure to each antibiotic, for a vancomycin-susceptible strain (JKD6009) and a vancomycin-intermediate strain (JKD6008). Exploration of this data set by multivariate analysis using a novel implementation of nonnegative matrix factorization (NMF) revealed very different responses for mRNA and sRNA. Where mRNA responses clustered with strain or growth phase conditions, the sRNA responses were predominantly linked to antibiotic exposure, including sRNA responses that were specific for particular antibiotics. A remarkable feature of the antimicrobial response was the prominence of antisense sRNAs to genes encoding proteins involved in protein synthesis and ribosomal function. This study has defined a large sRNA repertoire in epidemic ST239 MRSA and shown for the first time that a subset of sRNAs are part of a coordinated transcriptional response to specific antimicrobial exposures in S. aureus. These data provide a framework for interrogating the role of staphylococcal sRNAs in antimicrobial resistance and exploring new avenues for sRNA-based antimicrobial therapies.
authors.affiliation: Austin Centre for Infection Research, Infectious Diseases Department, Austin Health, Heidelberg, Victoria, Australia. Benjamin.Howden@austin.org.au
authors.forename: Benjamin P
authors.initials: BP
authors.lastname: Howden
authors.forename: Marie
authors.initials: M
authors.lastname: Beaume
authors.forename: Paul F
authors.initials: PF
authors.lastname: Harrison
authors.forename: David
authors.initials: D
authors.lastname: Hernandez
authors.forename: Jacques
authors.initials: J
authors.lastname: Schrenzel
authors.forename: Torsten
authors.initials: T
authors.lastname: Seemann
authors.forename: Patrice
authors.initials: P
authors.lastname: Francois
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Stinear
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D000069349:Linezolid; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology; D023303:Oxazolidinones / Q000494:pharmacology; D014176:Protein Biosynthesis; D012329:RNA, Bacterial / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D058727:RNA, Small Untranslated / Q000235:genetics / Q000378:metabolism*; D017423:Sequence Analysis, RNA; D000078304:Tigecycline; D014158:Transcription, Genetic; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D023303:Oxazolidinones; D012329:RNA, Bacterial; D012333:RNA, Messenger; D058727:RNA, Small Untranslated; C443755:ceftobiprole; D014640:Vancomycin; D000078304:Tigecycline; D008911:Minocycline; D000069349:Linezolid